Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors

被引：0

作者：

Tenaillon, Anne ^{[1
]}

Orbach, Daniel ^{[1
]}

机构：

[1] Inst Curie, Ctr Integre Soins & Rech Oncol Enfant Adolescent &, 26 rue Ulm, F-75005 Paris, France

来源：

BULLETIN DU CANCER | 2023年 / 110卷 / 04期

关键词：

Inflammatory myofibroblastic tumor; Targeted therapy; ALK-positive; Crizotinib; Children;

D O I：

10.1016/j.bulcan.2022.12.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：248 / 249

页数：2

共 50 条

[41] Crizotinib in Advanced ALK-Positive NSCLC - A Retrospective Multicenter Study in the Slovak Republic
Kasan, Peter
Berzinec, Peter
Plank, Lukas
Andrasina, Igor
Godal, Robert
Mazal, Juraj
Cipkova, Andrea
Cerna, Maria
Denkova, Lucia
Chowaniecova, Gabriela
Kuliskova, Iveta
Kuzmova, Helena
Martak, Marian
Pribulova, Zuzana
Reckova, Marian
Vesela, Milada
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S529 - S529
[42] ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
Itchins, Malinda
Liang, Shirley
Brown, Chris
Barnes, Tristan
Marx, Gavin
Chin, Venessa
Kao, Steven
Yip, Po Yee
Mersiades, Antony J.
Nagrial, Adnan
Bray, Victoria
Peters, Geoffrey
Parakh, Sagun
Garg, Kavita
Li, Bob T.
Mckay, Matthew
O'Byrne, Kenneth
John, Thomas
Gill, Anthony J.
Molloy, Mark P.
Solomon, Benjamin J.
Pavlakis, Nick
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (09):
[43] Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl
Gaudichon, Jeremie
Jeanne-Pasquier, Corinne
Deparis, Marianna
Veyssiere, Alexis
Heyndrickx, Maxime
Minckes, Odile
Orbach, Daniel
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (04) : 308 - 311
[44] The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors
Felkai, Luca
Banusz, Rita
Kovalszky, Ilona
Sapi, Zoltan
Garami, Miklos
Papp, Gergo
Karaszi, Katalin
Varga, Edit
Csoka, Monika
PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 217 - 224
[45] Treatment modalities of ALK-positive relapsed/refractory inflammatory myofibroblastic tumor of the brain and lungs in 7-year-old girl: case-based reviews
Supapitch Chanthong
Lalita Sathitsamitphong
Rungrote Natesirinilkul
Pimlak Charoenkwan
Songkiet Suwansirikul
Chane Choed-Amphai
Child's Nervous System, 2023, 39 : 331 - 342
[46] Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Lin, Jessica J.
Zhu, Viola W.
Schoenfeld, Adam J.
Yeap, Beow Y.
Saxena, Ashish
Ferris, Lorin A.
Dagogo-Jack, Ibiayi
Farago, Anna F.
Taber, Angela
Traynor, Anne
Menon, Smitha
Gainor, Justin F.
Lennerz, Jochen K.
Plodkowski, Andrew J.
Digumarthy, Subba R.
Ignatius, Sai-Hong
Shaw, Alice T.
Riely, Gregory J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1530 - 1538
[47] Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib
Olmez, O. F.
Bilici, A.
Gursoy, P.
Cubukcu, E.
Sakin, A.
Korkmaz, T.
Cil, I.
Cakar, B.
Menekse, S.
Demir, T.
Acikgoz, O.
Hamdard, J.
PULMONOLOGY, 2023, 29 (06): : 478 - 485
[48] Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-Positive Advanced NSCLC Patient
Yang, S.
Chen, X.
Ma, S.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1950 - S1950
[49] Quality of Life for Crizotinib vs. Chemotherapy in Asian ALK-Positive NSCLC Patients
Blackhall, Fiona
Mok, Tony
Nishio, Makoto
Kim, Dong-Wan
Wilner, Keith D.
Reisman, Arlene
Iyer, Shrividya
Solomon, Benjamin J.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S378 - S379
[50] Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL
Sun, Xue
Fang, Xiaosheng
Jiang, Yujie
INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 108 - 111

← 1 2 3 4 5 →